SS
NGNE icon

SBI Securities’s Neurogene NGNE Stock Holding History

SBI Securities’s Portfolio NGNE Stock Details NGNE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$3.93K Hold
125
– – ﹤0.01% 2286
2026
Q1 		$2.52K Buy
125
+100
+400% +$1.94K ﹤0.01% 2334
2025
Q4 		$515 Sell
25
-2
-7% -$50 ﹤0.01% 2868
2025
Q3 		$468 Buy
27
+2
+8% +$40 ﹤0.01% 2996
2025
Q2 		$374 Buy
25
+10
+67% +$157 ﹤0.01% 3081
2025
Q1 		$176 Sell
15
-20
-57% -$347 ﹤0.01% 3263
2024
Q4 		$800 Buy
+35
New +$1.3K ﹤0.01% 2712

Other funds holding NGNE

SB
Samsara BioCapital Palo Alto, California $1.22B AUM 242.83% 1-Year Est. Return
CC
Casdin Capital New York $2B AUM 147.21% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.06B AUM 215.32% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $80.2B AUM 51.53% 1-Year Est. Return
TECP
Trails Edge Capital Partners Atlanta, Georgia $630M AUM
Toronto Dominion Bank
Toronto Dominion Bank Toronto, Ontario, Ontario, Canada $86.4B AUM 59.51% 1-Year Est. Return

SBI Securities's NGNE Position: Q2 2026 in Review

SBI Securities held its Neurogene (NGNE) position steady in Q2 2026 at 125 shares worth $3.93K. The position accounts for ﹤0.01% of the portfolio, ranked #2286.

SBI Securities first reported a position in NGNE in Q4 2024 and has held it in 7 quarters since. 112 funds tracked by Wall St. Rank hold NGNE as of Q2 2026.

  • SBI Securities held 125 shares of Neurogene worth $3.93K as of Q2 2026.
  • SBI Securities left its Neurogene share count unchanged in Q2 2026.
  • Neurogene made up ﹤0.01% of SBI Securities's portfolio in Q2 2026, its #2286 holding.
  • SBI Securities first reported a position in Neurogene in Q4 2024 and has held it in 7 quarters since.
  • 112 funds tracked by Wall St. Rank held Neurogene as of Q2 2026.

Based on SBI Securities's 13F filing for Q2 2026, filed 23 Jul 2026.